Clinical trials: Dementia Moderate, open to volunteers
Dementia
Exploratory Study of the Effects of Peptide PMS-001 on Long-Delay Recall in Patients With Moderate to Severe Dementia
This is a single-center, randomized, double-blind, placebo-controlled study. Patients will be randomly assigned to either the peptide intervention group (with dose escalation at 15mg, 30mg, 60mg, and 75mg) or the placebo control…
- Trial name
- NCT06946511
- Testing
- Peptide PMS-001 Intravenous Injection
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Ruijin Hospital
Alzheimer Disease
A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease
The purpose of this study is to evaluate the safety and tolerability of NSC001 on in patients with mild to moderate Alzheimer's disease and to evaluate the influence of the compound on cognitive function.
- Trial name
- NCT06995573
- Testing
- NSC001
- Where
- 10 sites in Austria, Germany
- Volunteers
- 90 people
- Sponsor
- NSC-Therapeutics
Primary Progressive Aphasia
Semantic Rehabilitation for Patients With Primary Progressive Semantic Aphasia
This project aims to measure the effect of a semantic rehabilitation protocol for patients with primary progressive semantic aphasia and using the SCED methodology.
- Trial name
- SCED-APPvs (NCT04957537)
- Testing
- semantic therapy and semantic re-education
- Where
- France
- Volunteers
- 15 people
- Sponsor
- University Hospital, Toulouse
Dementia
CST+MST Intervention on People Living With Mild-to-moderate Dementia
Non-pharmacological interventions such as Cognitive Stimulation Therapy (CST) and physical activity are recommended for people living with mild-to-moderate dementia.
- Trial name
- CST+MST (NCT07625241)
- Testing
- Cognitive Stimulation Therapy and Motor Stimulation Treatment
- Where
- Italy
- Volunteers
- 421 people
- Sponsor
- Istituto Superiore di Sanità
Alzheimer Disease
A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)
The primary purpose of this study is to evaluate the safety and tolerability of Zunveyl® over 12 weeks of routine clinical use in adults with mild to moderate Alzheimer's disease.
- Trial name
- RESOLVE (NCT07633470)
- Testing
- Zunveyl®
- Where
- 22 sites in United States
- Volunteers
- 150 people
- Sponsor
- Alpha Cognition, Inc
Alzheimer's Disease, Lewy Body Dementia
Pulsed Electromagnetic Field Treatment With Dementia Patients
An open label pilot study in mild to moderate AD/ADRD patients to assess the effects of treatment with ECHS AD/ADRD pulsed electromagnetic treatment device on disease progression. Enrolled patients will receive active devices.
- Conditions
- Alzheimer's Disease, Lewy Body Dementia, Vascular Dementia
- Trial name
- NCT06862557
- Testing
- ECHS AD Device
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Herrick Medical LLC
Mild to Moderate Dementia
The Feasibility and the Efficacy of the Full-immersive Virtual Reality Cognitive Training in Patients With Mild or Moderate Dementia
This project will explore the feasibility and efficacy of the fully immersive virtual reality leisure cognitive training tool developed by Chang Gung University in patients with mild to moderate dementia.
- Trial name
- NCT07033468
- Testing
- VR-WLC, CTL-VR
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Chang Gung Memorial Hospital